Viridian Therapeutics
VRDN
10 hedge funds and large institutions have $1.32M invested in Viridian Therapeutics in 2015 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and closing their positions.
111% more capital invested
Capital invested by funds: $626K → $1.32M (+$692K)
100% more funds holding
Funds holding: 5 → 10 (+5)
Top Buyers
| 1 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$409K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$198K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$125K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$67.6K |
| 5 |
WPC
White Pine Capital
Bloomington,
Minnesota
|
+$61.3K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
1
Perkins Capital Management
Wayzata,
Minnesota
| $449K | +$409K | +708 | +320% |
|
|
HA
2
Heartland Advisors
Milwaukee,
Wisconsin
| $430K | +$21.4K | +37 | +4% |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $166K | +$198K | +343 | New |
|
|
4
Bank of America
Charlotte,
North Carolina
| $104K | +$125K | +216 | New |
|
|
VKH
5
Virtu KCG Holdings
New York
| $56K | +$67.6K | +117 | New |
|
|
WPC
6
White Pine Capital
Bloomington,
Minnesota
| $51K | +$61.3K | +106 | New |
|
7
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $34K | +$39.9K | +69 | New |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $17K | +$15.6K | +27 | +300% |
|
9
UBS Group
Zurich,
Switzerland
| $8K | +$2.89K | +5 | +42% |
|
10
Citigroup
New York
| $3K | +$2.31K | +4 | +200% |
|
VRDN Hedge Fund Activity: Q1 2015 in Review
10 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q1 2015, worth a combined $1.32M — up 111% from $626K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new VRDN positions and 0 closed out — a net gain of 5 holders — while 5 added to existing stakes and 0 trimmed.
The largest buyer was Perkins Capital Management, adding an estimated $409K.
- 10 institutional investors held Viridian Therapeutics (VRDN) as of Q1 2015, up from 5 in Q4 2014.
- Funds reported $1.32M of Viridian Therapeutics stock for Q1 2015, up 111% quarter-over-quarter.
- 5 funds opened new Viridian Therapeutics positions in Q1 2015 and 0 closed out, a net change of +5 holders.
- The largest Viridian Therapeutics buyer in Q1 2015 was Perkins Capital Management, an estimated $409K added.
Based on aggregated 13F filings for Q1 2015.